View Future GrowthWOLVES HAND 과거 순이익 실적과거 기준 점검 6/6WOLVES HAND은 연평균 19.2%의 비율로 수입이 증가해 온 반면, Healthcare 산업은 수입이 5.8% 증가했습니다. 매출은 연평균 8.6%의 비율로 증가했습니다. WOLVES HAND의 자기자본이익률은 26.4%이고 순이익률은 14.9%입니다.핵심 정보19.21%순이익 성장률17.28%주당순이익(EPS) 성장률Healthcare 산업 성장률7.93%매출 성장률8.64%자기자본이익률26.43%순이익률14.87%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 16Third quarter 2026 earnings released: EPS: JP¥39.37 (vs JP¥16.59 in 3Q 2025)Third quarter 2026 results: EPS: JP¥39.37 (up from JP¥16.59 in 3Q 2025). Revenue: JP¥1.52b (up 18% from 3Q 2025). Net income: JP¥297.0m (up 140% from 3Q 2025). Profit margin: 20% (up from 9.6% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Japan.Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥17.97 (vs JP¥16.59 in 2Q 2025)Second quarter 2026 results: EPS: JP¥17.97 (up from JP¥16.59 in 2Q 2025). Revenue: JP¥1.43b (up 11% from 2Q 2025). Net income: JP¥135.0m (up 8.9% from 2Q 2025). Profit margin: 9.4% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Japan.공시 • Dec 27WOLVES HAND Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026WOLVES HAND Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026Reported Earnings • Nov 16First quarter 2026 earnings released: EPS: JP¥22.06 (vs JP¥33.38 in 1Q 2025)First quarter 2026 results: EPS: JP¥22.06 (down from JP¥33.38 in 1Q 2025). Revenue: JP¥1.37b (down 7.0% from 1Q 2025). Net income: JP¥165.0m (down 34% from 1Q 2025). Profit margin: 12% (down from 17% in 1Q 2025). The decrease in margin was driven by lower revenue.공시 • Sep 27WOLVES HAND Co., Ltd. to Report Q1, 2026 Results on Nov 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q1, 2026 results on Nov 14, 2025공시 • Jun 24WOLVES HAND Co., Ltd. to Report Fiscal Year 2025 Results on Aug 15, 2025WOLVES HAND Co., Ltd. announced that they will report fiscal year 2025 results on Aug 15, 2025모든 업데이트 보기Recent updatesReported Earnings • May 16Third quarter 2026 earnings released: EPS: JP¥39.37 (vs JP¥16.59 in 3Q 2025)Third quarter 2026 results: EPS: JP¥39.37 (up from JP¥16.59 in 3Q 2025). Revenue: JP¥1.52b (up 18% from 3Q 2025). Net income: JP¥297.0m (up 140% from 3Q 2025). Profit margin: 20% (up from 9.6% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Japan.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to JP¥1,803, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Healthcare industry in Japan. Total returns to shareholders of 190% over the past year.Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥17.97 (vs JP¥16.59 in 2Q 2025)Second quarter 2026 results: EPS: JP¥17.97 (up from JP¥16.59 in 2Q 2025). Revenue: JP¥1.43b (up 11% from 2Q 2025). Net income: JP¥135.0m (up 8.9% from 2Q 2025). Profit margin: 9.4% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Japan.공시 • Dec 27WOLVES HAND Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026WOLVES HAND Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026분석 기사 • Dec 19Investors Should Be Encouraged By WOLVES HAND's (TSE:194A) Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥1,667, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 15x in the Healthcare industry in Japan. Total returns to shareholders of 121% over the past year.Reported Earnings • Nov 16First quarter 2026 earnings released: EPS: JP¥22.06 (vs JP¥33.38 in 1Q 2025)First quarter 2026 results: EPS: JP¥22.06 (down from JP¥33.38 in 1Q 2025). Revenue: JP¥1.37b (down 7.0% from 1Q 2025). Net income: JP¥165.0m (down 34% from 1Q 2025). Profit margin: 12% (down from 17% in 1Q 2025). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥1,594, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 13x in the Healthcare industry in Japan. Total returns to shareholders of 88% over the past year.분석 기사 • Oct 28WOLVES HAND (TSE:194A) Has A Pretty Healthy Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improves as stock rises 23%After last week's 23% share price gain to JP¥1,331, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 53% over the past year.New Risk • Oct 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks High level of debt (60% net debt to equity). Market cap is less than US$100m (JP¥8.11b market cap, or US$53.8m).분석 기사 • Oct 03Investors Still Aren't Entirely Convinced By WOLVES HAND Co., Ltd.'s (TSE:194A) Earnings Despite 26% Price JumpDespite an already strong run, WOLVES HAND Co., Ltd. ( TSE:194A ) shares have been powering on, with a gain of 26% in...공시 • Sep 27WOLVES HAND Co., Ltd. to Report Q1, 2026 Results on Nov 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q1, 2026 results on Nov 14, 2025Valuation Update With 7 Day Price Move • Sep 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥1,097, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 1.0% over the past year.분석 기사 • Aug 19Even With A 34% Surge, Cautious Investors Are Not Rewarding WOLVES HAND Co., Ltd.'s (TSE:194A) Performance CompletelyThe WOLVES HAND Co., Ltd. ( TSE:194A ) share price has done very well over the last month, posting an excellent gain of...공시 • Aug 15WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025.공시 • Jun 24WOLVES HAND Co., Ltd. to Report Fiscal Year 2025 Results on Aug 15, 2025WOLVES HAND Co., Ltd. announced that they will report fiscal year 2025 results on Aug 15, 2025New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (89% net debt to equity). Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (JP¥5.34b market cap, or US$36.9m).공시 • Apr 23WOLVES HAND Co., Ltd. to Report Q3, 2025 Results on May 15, 2025WOLVES HAND Co., Ltd. announced that they will report Q3, 2025 results on May 15, 2025New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (98% net debt to equity). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (JP¥4.72b market cap, or US$33.0m).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥587, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 12x in the Healthcare industry in Japan.공시 • Jan 24WOLVES HAND Co., Ltd. to Report Q2, 2025 Results on Feb 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q2, 2025 results on Feb 14, 2025공시 • Jan 08WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda.WOLVES HAND Co., Ltd. (TSE:194A) acquired Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025. A cash consideration will be paid by WOLVES HAND Co., Ltd. As part of consideration, an undisclosed value is paid towards assets of Animal hospital business at Yasuda Animal Hospital. The expected completion of the transaction is January 6, 2025. WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to JP¥980, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 16x in the Healthcare industry in Japan.Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥1,125, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 15x in the Healthcare industry in Japan.Reported Earnings • Aug 14Full year 2024 earnings released: EPS: JP¥75.15 (vs JP¥68.16 in FY 2023)Full year 2024 results: EPS: JP¥75.15 (up from JP¥68.16 in FY 2023). Revenue: JP¥4.99b (up 7.3% from FY 2023). Net income: JP¥558.0m (up 10% from FY 2023). Profit margin: 11% (in line with FY 2023).공시 • Aug 09WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd.WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd. on August 8, 2024. For the period ending August 31, 2023, Soyokaze Co., Ltd. reported total revenue of ¥290 million, EBIT of ¥29 million and net income of ¥22 million. As of August 31, 2023, Soyokaze Co., Ltd. reported total assets of ¥191 million and total common equity of ¥99 million.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥783, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 15x in the Healthcare industry in Japan.Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to JP¥1,149, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 17x in the Healthcare industry in Japan.Board Change • Jun 30High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Outside Director Hiroshi Nakata was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Jun 21WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million.WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 686,400 Price\Range: ¥770 Discount Per Security: ¥61.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 176,700 Price\Range: ¥770 Discount Per Security: ¥61.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,000 Price\Range: ¥770 Discount Per Security: ¥61.6 Transaction Features: Sponsor Backed Offering매출 및 비용 세부 내역WOLVES HAND가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSE:194A 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Mar 265,978889522031 Dec 255,749716476030 Sep 255,577691413030 Jun 255,463593451031 Mar 255,270549450030 Jun 244,990558399030 Jun 234,651506482030 Jun 224,2953164980양질의 수익: 194A는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 194A의 현재 순 이익률 (14.9%)은 지난해 (10.4%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 194A의 수익은 지난 5년 동안 연평균 19.2% 증가했습니다.성장 가속화: 지난 1년간 194A 의 수익 증가율(61.9%)은 연간 평균(19.2%)을 초과합니다.수익 대 산업: 194A의 지난 1년 수익 증가율(61.9%)은 Healthcare 업계의 5.6%를 상회했습니다.자기자본이익률높은 ROE: 194A의 자본 수익률(26.4%)은 높음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/17 04:54종가2026/05/15 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스WOLVES HAND Co., Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Koichi HariyaIchiyoshi Research Institute Inc.
Reported Earnings • May 16Third quarter 2026 earnings released: EPS: JP¥39.37 (vs JP¥16.59 in 3Q 2025)Third quarter 2026 results: EPS: JP¥39.37 (up from JP¥16.59 in 3Q 2025). Revenue: JP¥1.52b (up 18% from 3Q 2025). Net income: JP¥297.0m (up 140% from 3Q 2025). Profit margin: 20% (up from 9.6% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Japan.
Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥17.97 (vs JP¥16.59 in 2Q 2025)Second quarter 2026 results: EPS: JP¥17.97 (up from JP¥16.59 in 2Q 2025). Revenue: JP¥1.43b (up 11% from 2Q 2025). Net income: JP¥135.0m (up 8.9% from 2Q 2025). Profit margin: 9.4% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Japan.
공시 • Dec 27WOLVES HAND Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026WOLVES HAND Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026
Reported Earnings • Nov 16First quarter 2026 earnings released: EPS: JP¥22.06 (vs JP¥33.38 in 1Q 2025)First quarter 2026 results: EPS: JP¥22.06 (down from JP¥33.38 in 1Q 2025). Revenue: JP¥1.37b (down 7.0% from 1Q 2025). Net income: JP¥165.0m (down 34% from 1Q 2025). Profit margin: 12% (down from 17% in 1Q 2025). The decrease in margin was driven by lower revenue.
공시 • Sep 27WOLVES HAND Co., Ltd. to Report Q1, 2026 Results on Nov 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q1, 2026 results on Nov 14, 2025
공시 • Jun 24WOLVES HAND Co., Ltd. to Report Fiscal Year 2025 Results on Aug 15, 2025WOLVES HAND Co., Ltd. announced that they will report fiscal year 2025 results on Aug 15, 2025
Reported Earnings • May 16Third quarter 2026 earnings released: EPS: JP¥39.37 (vs JP¥16.59 in 3Q 2025)Third quarter 2026 results: EPS: JP¥39.37 (up from JP¥16.59 in 3Q 2025). Revenue: JP¥1.52b (up 18% from 3Q 2025). Net income: JP¥297.0m (up 140% from 3Q 2025). Profit margin: 20% (up from 9.6% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Japan.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to JP¥1,803, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Healthcare industry in Japan. Total returns to shareholders of 190% over the past year.
Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥17.97 (vs JP¥16.59 in 2Q 2025)Second quarter 2026 results: EPS: JP¥17.97 (up from JP¥16.59 in 2Q 2025). Revenue: JP¥1.43b (up 11% from 2Q 2025). Net income: JP¥135.0m (up 8.9% from 2Q 2025). Profit margin: 9.4% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Japan.
공시 • Dec 27WOLVES HAND Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026WOLVES HAND Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026
분석 기사 • Dec 19Investors Should Be Encouraged By WOLVES HAND's (TSE:194A) Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥1,667, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 15x in the Healthcare industry in Japan. Total returns to shareholders of 121% over the past year.
Reported Earnings • Nov 16First quarter 2026 earnings released: EPS: JP¥22.06 (vs JP¥33.38 in 1Q 2025)First quarter 2026 results: EPS: JP¥22.06 (down from JP¥33.38 in 1Q 2025). Revenue: JP¥1.37b (down 7.0% from 1Q 2025). Net income: JP¥165.0m (down 34% from 1Q 2025). Profit margin: 12% (down from 17% in 1Q 2025). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥1,594, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 13x in the Healthcare industry in Japan. Total returns to shareholders of 88% over the past year.
분석 기사 • Oct 28WOLVES HAND (TSE:194A) Has A Pretty Healthy Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improves as stock rises 23%After last week's 23% share price gain to JP¥1,331, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 53% over the past year.
New Risk • Oct 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks High level of debt (60% net debt to equity). Market cap is less than US$100m (JP¥8.11b market cap, or US$53.8m).
분석 기사 • Oct 03Investors Still Aren't Entirely Convinced By WOLVES HAND Co., Ltd.'s (TSE:194A) Earnings Despite 26% Price JumpDespite an already strong run, WOLVES HAND Co., Ltd. ( TSE:194A ) shares have been powering on, with a gain of 26% in...
공시 • Sep 27WOLVES HAND Co., Ltd. to Report Q1, 2026 Results on Nov 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q1, 2026 results on Nov 14, 2025
Valuation Update With 7 Day Price Move • Sep 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥1,097, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 1.0% over the past year.
분석 기사 • Aug 19Even With A 34% Surge, Cautious Investors Are Not Rewarding WOLVES HAND Co., Ltd.'s (TSE:194A) Performance CompletelyThe WOLVES HAND Co., Ltd. ( TSE:194A ) share price has done very well over the last month, posting an excellent gain of...
공시 • Aug 15WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025.
공시 • Jun 24WOLVES HAND Co., Ltd. to Report Fiscal Year 2025 Results on Aug 15, 2025WOLVES HAND Co., Ltd. announced that they will report fiscal year 2025 results on Aug 15, 2025
New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (89% net debt to equity). Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (JP¥5.34b market cap, or US$36.9m).
공시 • Apr 23WOLVES HAND Co., Ltd. to Report Q3, 2025 Results on May 15, 2025WOLVES HAND Co., Ltd. announced that they will report Q3, 2025 results on May 15, 2025
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (98% net debt to equity). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (JP¥4.72b market cap, or US$33.0m).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥587, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 12x in the Healthcare industry in Japan.
공시 • Jan 24WOLVES HAND Co., Ltd. to Report Q2, 2025 Results on Feb 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q2, 2025 results on Feb 14, 2025
공시 • Jan 08WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda.WOLVES HAND Co., Ltd. (TSE:194A) acquired Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025. A cash consideration will be paid by WOLVES HAND Co., Ltd. As part of consideration, an undisclosed value is paid towards assets of Animal hospital business at Yasuda Animal Hospital. The expected completion of the transaction is January 6, 2025. WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to JP¥980, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 16x in the Healthcare industry in Japan.
Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥1,125, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 15x in the Healthcare industry in Japan.
Reported Earnings • Aug 14Full year 2024 earnings released: EPS: JP¥75.15 (vs JP¥68.16 in FY 2023)Full year 2024 results: EPS: JP¥75.15 (up from JP¥68.16 in FY 2023). Revenue: JP¥4.99b (up 7.3% from FY 2023). Net income: JP¥558.0m (up 10% from FY 2023). Profit margin: 11% (in line with FY 2023).
공시 • Aug 09WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd.WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd. on August 8, 2024. For the period ending August 31, 2023, Soyokaze Co., Ltd. reported total revenue of ¥290 million, EBIT of ¥29 million and net income of ¥22 million. As of August 31, 2023, Soyokaze Co., Ltd. reported total assets of ¥191 million and total common equity of ¥99 million.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥783, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 15x in the Healthcare industry in Japan.
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to JP¥1,149, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 17x in the Healthcare industry in Japan.
Board Change • Jun 30High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Outside Director Hiroshi Nakata was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Jun 21WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million.WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 686,400 Price\Range: ¥770 Discount Per Security: ¥61.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 176,700 Price\Range: ¥770 Discount Per Security: ¥61.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,000 Price\Range: ¥770 Discount Per Security: ¥61.6 Transaction Features: Sponsor Backed Offering